MyFinsight
Home
Blog
About
US
$809,079K
(3568.79%↑ Y/Y)
Europe
$119,010K
(460.15%↑ Y/Y)
Non USOr Europe
$83,673K
(805.65%↑ Y/Y)
US
$9,863K
(-97.27%↓ Y/Y)
Europe
$5,508K
(-94.07%↓ Y/Y)
Non USOr Europe
$3,090K
(-91.81%↓ Y/Y)
US
$58,000K
(5.17%↑ Y/Y)
Europe
$24,323K
(16.01%↑ Y/Y)
Non USOr Europe
$7,441K
(57.25%↑ Y/Y)
Europe
$22,678K
(3.42%↑ Y/Y)
US
$18,545K
(15.77%↑ Y/Y)
Non USOr Europe
$10,899K
(22.13%↑ Y/Y)
Amvuttra
$1,011,762K
(105.66%↑ Y/Y)
ONPATTRO
$18,461K
(-64.86%↓ Y/Y)
GIVLAARI
$89,764K
(11.03%↑ Y/Y)
OXLUMO
$52,122K
(11.20%↑ Y/Y)
TTR
$1,030,223K
(89.21%↑ Y/Y)
Rare
$141,886K
(11.09%↑ Y/Y)
Roche
$41,888K
(129.31%↑ Y/Y)
Regeneron
Pharmaceuticals Incorporation
$5,020K
(-84.57%↓ Y/Y)
Other Collaborations
$257K
(-97.60%↓ Y/Y)
Product
$1,172,109K
(74.37%↑ Y/Y)
Royalty
$71,674K
(79.27%↑ Y/Y)
Collaborations
$47,165K
(-23.30%↓ Y/Y)
Total revenues
$1,290,948K
(66.86%↑ Y/Y)
Income (loss) from
operations
$231,441K
(1528.74%↑ Y/Y)
Total operating costs
and expenses
$1,059,507K
(34.13%↑ Y/Y)
Income (loss) before
income taxes
$177,806K
(602.87%↑ Y/Y)
Total other expense,
net
-$53,635K
(-179.95%↓ Y/Y)
Interest income
$28,143K
(2.39%↑ Y/Y)
Other income
(expense), net
$273K
(104.27%↑ Y/Y)
Research and development
$413,134K
(27.66%↑ Y/Y)
Selling, general and
administrative
$347,922K
(7.61%↑ Y/Y)
Cost of goods sold
$298,261K
(110.00%↑ Y/Y)
Cost of
collaborations and royalties
$190K
(-79.44%↓ Y/Y)
Net income (loss)
$164,494K
(348.19%↑ Y/Y)
Provision for income taxes
$13,312K
(-56.95%↓ Y/Y)
Interest expense
$82,051K
(103.87%↑ Y/Y)
Comprehensive income (loss)
$157,250K
(367.83%↑ Y/Y)
Total other
comprehensive (gain) income
-$7,244K
(-195.76%↓ Y/Y)
Defined benefit pension
plans, net of tax
-$89K
(-67.92%↓ Y/Y)
Foreign currency
translation (gaines) losss
-$3,698K
(-147.08%↓ Y/Y)
Unrealized (gaines) losss
on marketable...
-$3,635K
(-959.77%↓ Y/Y)
Back
Back
Income Statement
logo (21)-svg-svg
ALNYLAM PHARMACEUTICALS, INC. (ALNY)
logo (21)-svg-svg
ALNYLAM PHARMACEUTICALS, INC. (ALNY)
source: myfinsight.com